BioXgen, a medical device company, has opened a Community Investment Round under Regulation Crowdfunding to advance development of a cardiac patch designed to prevent post-operative atrial fibrillation (POAF), the most common complication following open-heart surgery. The company aims to address a significant healthcare burden, as POAF affects roughly 50% of the 500,000 Americans undergoing such surgery annually, contributing approximately $9 billion in costs to the U.S. healthcare system and increasing risks of stroke, recurrent atrial fibrillation, kidney failure, and death.
Currently, no FDA-cleared device exists to prevent POAF, with surgeons relying on off-label pharmaceuticals for decades without substantial improvement. BioXgen's cardiac patch is placed directly on the heart's surface during surgery. Pre-clinical data published in Circulation shows POAF rates dropping from about 50% to under 5%, a tenfold reduction. Unpublished data from over 200 additional patients reportedly shows similar results. The company has completed a Q-submission to the FDA, solidifying a 510(k) regulatory pathway, which targets FDA clearance within 18 months if funding needs are met, with the goal of establishing the device as standard of care within 36 to 48 months.
The investment offering, hosted by DealMaker Securities, allows retail investors to participate with investments starting at $500, a departure from traditional institutional-only funding in this category. BioXgen emphasizes a lean structure with contracted manufacturing and a growing intellectual property portfolio. The leadership team includes Dr. David Skinner, President and CEO, who previously built and exited a medical company at a 10x return, and Dr. John P. Konhilas, Chief Science Officer, a former physiology professor with over 30 years of cardiac research experience and expertise in regulatory pathways. The founders will present the investment pitch in a live webinar on April 7, 2025, with registration available at https://dnagency.lpages.co/bioxgen-investor-presentation/.
The implications of this development are substantial for patients, healthcare providers, and the medical device industry. If successful, the cardiac patch could reduce postoperative complications, lower healthcare costs, and set a new standard in cardiac care. For investors, the Reg CF offering provides rare access to early-stage medical innovation. The offering details and investment opportunity can be viewed at https://invest.bioxgen.life/, with the company's Form C filing available via the same link. This initiative highlights a growing trend of democratizing investment in high-impact medical solutions, potentially accelerating the path to market for critical technologies.
